Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-119 pembrolizumab versus physician's choice chemotherapy in metastatic triple-negative breast cancer
NL-OMON46885Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall survival in subjects with PD-L1 positive tumors and Overall survival in all subjects. Started Mar 2016; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON46885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46885.